Table 2 Comparison of baseline demographics, and clinical/serological SLE-manifestations with HCQ use following ESRD diagnosisa
|  | HCQ use N = 31 | No HCQ use N = 28 | p-value |
|---|---|---|---|
Age at ESRD onset, median (IQR), years | 33 (26, 48) | 47 (32, 54) | 0.068 |
Race, n(%) Black or African-American Other | 14 (45) | 18 (64) | 0.315 |
Hispanic or Latino, n(%) | 16 (52) | 9 (32) | 0.315 |
Women, n(%) | 25 (81) | 23 (82) | 0.883 |
Time from ESRD onset to last documented visit, median(IQR), months | 33 (19, 60) | 43 (9, 89) | 0.564 |
Central nervous system manifestations, n(%) | 6 (20) | 1 (4) | 0.055 |
Arthritis, n(%) | 10 (32) | 1 (4) | 0.005 |
Rash, n(%) | 4 (13) | 2 (7) | 0.439 |
Oral ulcers, n(%) | 1 (4) | 1 (4) | 0.980 |
Alopecia, n(%) | 1 (4) | 2 (7) | 0.532 |
Serositis, n(%) | 1 (4) | 2 (7) | 0.532 |
Leukopenia, n(%) | 17 (55) | 17 (60) | 0.648 |
Thrombocytopenia, n(%) | 15 (48) | 20 (71) | 0.072 |
Low complement, n(%) | 15 (54) | 16 (57) | 0.788 |
Elevated anti-dsDNA, n(%) | 13 (46) | 7 (25) | 0.094 |
Corticosteroid use, n(%) | 28 (90) | 20 (74) | 0.102 |
Immunosuppressive use, n(%)b | 22 (71) | 12 (43) | 0.029 |
At least one rheumatology visit post-ESRD, n(%) | 26 (87) | 17 (61) | 0.024 |
History of anti-phospholipid syndrome, n(%) | 4 (13) | 2 (7) | 0.493 |
History of deep vein thrombosis, n(%) | 4 (13) | 3 (11) | 0.834 |
Renal transplantation after ESRD, n(%) | 10 (32) | 7 (25) | 0.539 |